Sfoglia per AUTORE
MOSCA A
Collezione AOU Novara

  

Items : 16

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? in European urology oncology / Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21.

2024
ASL Cuneo 2
AOU Novara

Porta C; Battelli N; Bracarda S; Sorgentoni G; Monteiro FSM; Mollica V; Rizzo A; Zabalza IO; Bimbatti D; Soares A; Bisonni R; Rebuzzi SE; Roviello G; Incorvaia L; Morelli F; Santini D; Vau N; Bhuva D; Küronya Z; Mosca A; Landmesser J; Milella M; Messina C; Bassanelli M; Ortega C; Grillone F; Procopio G; Sunela K; Caffo O; et alii...

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1). in Clinical genitourinary cancer / Clin Genitourin Cancer. 2023 Oct;21(5):e309-e319.e1. doi: 10.1016/j.clgc.2023.03.006. Epub 2023 Mar

2023
AOU Novara

Santoni M; Massari F; Myint ZW; Iacovelli R; Pichler M; Basso U; Kopecky J; Kucharz J; Buti S; Salfi A; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Seront E; Calabrò F; Pinto A; Berardi R; et alii...

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2023 Nov;72(11):3665-3682. doi: 10.1007/s00262-023-03518-z. Epub 2023 Sep

2023
ASL Cuneo 2
AOU Novara

Santoni M; Porta C; Bellmunt J; Battelli N; Sorgentoni G; Landmesser J; Rizzo A; Mollica V; Zabalza IO; Zgura A; Incorvaia L; Ansari J; Pinto A; Soares A; Nunes F; Maluf F; Morelli F; Mosca A; Zakopoulou R; Bisonni R; Manneh R; Santini D; Inman E; Herchenhorn D; Kanesvaran R; Caitano M; Milella M; Kopecky J; Martignetti A; et alii...

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study. in Targeted oncology / Target Oncol. 2023 Jul;18(4):559-570. doi: 10.1007/s11523-023-00978-2. Epub 2023 Jun 27.

2023
AOU Novara

Santoni M; Massari F; Myint ZW; Iacovelli R; Pichler M; Basso U; Kopecky J; Kucharz J; Buti S; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Seront E; Calabrò F; Pinto A; et alii...

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. in Minerva urology and nephrology / Minerva Urol Nephrol. 2023 Aug;75(4):460-470. doi: 10.23736/S2724-6051.23.05369-7.

2023
AO Cuneo
ASL Cuneo 2
AOU Novara

Grande E; Santoni M; Buti S; Battelli N; Sorgentoni G; Pierantoni F; Monteiro FS; Rebuzzi SE; Roviello G; Soares A; Zabalza IO; Rizzo A; Bisonni R; Morelli F; Incorvaia L; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Messina C; Merler S; Landmesser J; Grillone F; Ortega C; Sunela K; Ansari J; Atzori F; Bassanelli M; et alii...

Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Sep;155:127-135. doi: 10.1016/j.ejca.2021.06.034. Epub 2021 Aug 6.

2021
AO Cuneo
ASL Asti
ASL Biella
ASL Cuneo 2
AOU Città della Salute di Torino
ASL Città di Torino
AOU Novara

Tucci M; Berruti A; Bianchi S; Ciccone G; Baier S; Gennari A; Amoroso D; Montagnani F; Comandone A; Bellissimo AR; Sacco C; Fea E; Vanella P; Valcamonico F; Zamparini M; Sirotova Z; Chiappino I; Dal Canton O; Masini C; Dalla Volta A; Prati V; Ortega C; Buttigliero C; Mosca A;

Toward a genome-based treatment landscape for renal cell carcinoma. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2019 Oct;142:141-152. doi: 10.1016/j.critrevonc.2019.07.020. Epub 2019 Aug 2

2019
AOU Novara

Massari F; Di Nunno V; Santoni M; Gatto L; Caserta C; Morelli F; Zafarana E; Carrozza F; Mosca A; Mollica V; Iacovelli R; Sabbatini R; Porta C; Bracarda S;

The effect of a treatment delay on outcome in metastatic renal cell carcinoma. in Urologic oncology / Urol Oncol. 2019 Aug;37(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005. Epub 2019 Mar 29.

2019
AOU Novara

Iacovelli R; Galli L; De Giorgi U; Porta C; Nolè F; Zucali P; Sabbatini R; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Buti S; Massari F; Masini C; Ricotta R; Biasco E; Lolli C; Gri N; Verri E; Miggiano C; Vitale MG; Tortora G;

Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. in Anticancer research / Anticancer Res. 2018 Oct;38(10):5773-5782. doi: 10.21873/anticanres.12916.

2018
AOU Novara

Santoni M; Piva F; De Giorgi U; Mosca A; Basso U; Santini D; Buti S; Lolli C; Terrone C; Maruzzo M; Iuliani M; Bersanelli M; Conti A; Mazzucchelli R; Montironi R; Burattini L; Berardi R;

Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? in Clinical genitourinary cancer / Clin Genitourin Cancer. 2018 Oct;16(5):355-359.e1. doi: 10.1016/j.clgc.2018.04.007. Epub 2018 May 7.

2018
AOU Novara

Iacovelli R; De Giorgi U; Galli L; Zucali P; Nolè F; Sabbatini R; Fraccon AP; Basso U; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Pasini F; Masini C; Massari F; Buti S; Sava T; Sacco C; Ricotta R; Sperduti I; Tortora G; Porta C;

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. in Anticancer research / Anticancer Res. 2018 Aug;38(8):4913-4918. doi: 10.21873/anticanres.12807.

2018
AOU Novara

Sbrana A; Biasco E; Paolieri F; Palesandro E; Caserta C; Iacovelli R; Detti B; Santini D; Mosca A; Morelli F; Fornarini G; De Giorgi U; Masini C; Galli L;

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. in Urologic oncology / Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29.

2017
AOU Novara

Iacovelli R; Cossu Rocca M; Galli L; De Giorgi U; Sabbatini R; Santoni M; Mosca A; Fornarini G; Massari F; Masini C; Bersanelli M; Biasco E; Lolli C; Guida A; Berardi R; Terrone C; Pastorino A; Ardizzoni A; Pinto C; Buti S; Nolè F; Tortora G;

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study. in Oncotarget / Oncotarget. 2016 Jun 28;7(26):40085-40094. doi: 10.18632/oncotarget.9485.

2016
AOU Novara

Verzoni E; De Giorgi U; Derosa L; Caffo O; Boccardo F; Facchini G; Porcu L; De Vincenzo F; Zaniboni A; Chiuri VE; Fratino L; Santini D; Adamo V; De Vivo R; Dinota A; Messina C; Ricotta R; Caserta C; Scavelli C; Susi M; Tartarone A; Surace G; Mosca A; Bruno M; Barni S; Grassi P; Procopio G;

Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. in The Journal of urology / J Urol. 2015 Jun;193(6):1905-10. doi: 10.1016/j.juro.2014.11.092. Epub 2014 Nov 26.

2015
AOU Novara

Iacovelli R; Farcomeni A; Sternberg CN; Cartenì G; Milella M; Santoni M; Cerbone L; Di Lorenzo G; Verzoni E; Ortega C; Sabbatini R; Ricotta R; Messina C; Lorusso V; Atzori F; De Vincenzo F; Sacco C; Boccardo F; Valduga F; Massari F; Baldazzi V; Cinieri S; Mosca A; Maria Ruggeri E; Berruti A; Procopio G;

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. in The Journal of urology / J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18.

2015
AOU Novara

Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; et alii...

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2013 Jun;49(9):2134-42. doi: 10.1016/j.ejca.2013.02.032. Epub 2013 Mar 18.

2013
AOU Novara

Iacovelli R; Cartenì G; Sternberg CN; Milella M; Santoni M; Di Lorenzo G; Ortega C; Sabbatini R; Ricotta R; Messina C; Lorusso V; Atzori F; De Vincenzo F; Sacco C; Boccardo F; Valduga F; Massari F; Baldazzi V; Cinieri S; Mosca A; Ruggeri EM; Berruti A; Cerbone L; Procopio G;